# TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

> **NCT07355257** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Zhongming Qiu** · enrollment: 30 (estimated)

## Conditions studied

- Inflammatory Myopathy

## Interventions

- **DRUG:** Telitacicept 240mg

## Key facts

- **NCT ID:** NCT07355257
- **Lead sponsor:** Zhongming Qiu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07355257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07355257, "TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07355257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*